Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy.

Abstract

The use of human umbilical cord blood-derived mesenchymal stem cells for cell transplantation therapy holds great promise for repairing spinal cord injury. Here we report the first clinical trial transplantation of human umbilical cord (hUCB)-derived mesenchymal stem cells (MSCs) into the spinal cord of a dog suspected to have fibrocartilaginous embolic myelopathy (FCEM) and that experienced a loss of deep pain sensation. Locomotor functions improved following transplantation in a dog. Based on our findings, we suggest that transplantation of hUCB-derived MSCs will have beneficial therapeutic effects on FCEM patients lacking deep pain sensation.

• Authors: Wook-Hun Chung, Seon-Ah Park, Jae-Hoon Lee, Dai-Jung Chung, Wo-Jong Yang, Eun-Hee Kang, Chi-Bong Choi, Hwa-Seok Chang, Dae-Hyun Kim, Soo-Han Hwang, Hoon Han, Hwi-Yool Kim
• Journal: Journal of veterinary science (J Vet Sci) Vol. 14 Issue 4 Pg. 495-7 ( 2013) ISSN: 1976-555X [Electronic] Korea (South)
• PMID: 23820160 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Animals
• Cartilage Diseases (etiology, therapy, veterinary)
• Cord Blood Stem Cell Transplantation (veterinary)
• Dog Diseases (etiology, therapy)
• Dogs
• Embolism (etiology, therapy, veterinary)
• Female
• Humans
• Mesenchymal Stem Cells (cytology, metabolism)
• Spinal Cord Diseases (etiology, therapy, veterinary)
• Treatment Outcome